Cognition Therapeutics
CGTX
26 hedge funds and large institutions have $4.58M invested in Cognition Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
116% more capital inflows, than outflows
Capital inflows: $2.21M | Capital outflows: $1.02M
30% more funds holding
Funds holding: 20 → 26 (+6)
1.5% more ownership
Funds ownership: 6.06% → 7.56% (+1.5%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Worth Venture Partners
Fort Lee,
New Jersey
|
+$676K |
| 2 |
Kestra Advisory Services
Austin,
Texas
|
+$553K |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
+$294K |
| 4 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$193K |
| 5 |
DI
Diligent Investors
Redlands,
California
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prosight Management
Dallas,
Texas
|
-$239K |
| 2 |
Millennium Management
New York
|
-$161K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$161K |
| 4 |
Two Sigma Investments
New York
|
-$159K |
| 5 |
Two Sigma Advisers
New York
|
-$157K |
CGTX Hedge Fund Activity: Q1 2022 in Review
26 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2022, worth a combined $4.58M — down 46% from $8.44M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CGTX positions and 4 closed out — a net gain of 6 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Worth Venture Partners, opening a new position worth an estimated $676K. The largest seller was Prosight Management, cutting an estimated $239K.
- 26 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2022, up from 20 in Q4 2021.
- Funds reported $4.58M of Cognition Therapeutics stock for Q1 2022, down 46% quarter-over-quarter.
- 10 funds opened new Cognition Therapeutics positions in Q1 2022 and 4 closed out, a net change of +6 holders.
- The largest Cognition Therapeutics buyer in Q1 2022 was Worth Venture Partners, an estimated $676K added.
- The largest Cognition Therapeutics seller in Q1 2022 was Prosight Management, an estimated $239K sold.
Based on aggregated 13F filings for Q1 2022.